Median Effective Dose of Remifentanil for the Prevention of Myoclonus Induced by Etomidate Injection
Etomidate, Myoclonus
About this trial
This is an interventional prevention trial for Etomidate
Eligibility Criteria
Inclusion Criteria: Ages ranged from 18 to 80. ASA # or # level. Exclusion Criteria: Allergy or contraindication to remifentanil or rocuronium; required for Central venipuncture catheterization; Abnormal liver or kidney function; Heavy drinking and long-term use of sedatives, analgesics or anti-anxiety drugs; Hearing and language impairment; Peripheral vascular disease; Severe cardiovascular disease or neurological disorders; Failure of one-time peripheral venipuncture; Infection of hand or wrist skin.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Age range of 18 to 40 years olds
Age range of 41 to 55 years olds
Age range of 56 to 70 years olds
Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.